Last mentioned: Mar 20, 2026
Regulatory Review
Target window for potential FDA/EMA orphan drug or breakthrough device designation filing.
Commercial Scalability Assessment
Evaluation of bio-foundry partnerships to standardize the production of engineered scaffolds.
Regulatory Submission
Expected filing for Advanced Therapy Medicinal Product (ATMP) designation with the MHRA.
Expanded Trials
Anticipated commencement of multi-center trials for broader pediatric applications.
Expanded Clinical Trials
Anticipated start of Phase II trials involving a larger cohort of pediatric patients with long-gap OA.
Phase I Clinical Data
Expected release of initial safety data from first-in-human pilot studies.
Breakthrough Announcement
First successful lab-grown oesophagus for pediatric use is unveiled to the public.
Breakthrough Announced
First successful development of a lab-grown oesophagus for pediatric use is reported.
A groundbreaking medical milestone has been achieved with the development of the first lab-grown oesophagus, offering a transformative treatment for children born with rare congenital conditions. This regenerative medicine breakthrough uses tissue engineering to create functional organs, potentially replacing invasive surgeries that currently rely on repositioning other digestive organs.
Researchers have successfully engineered the first lab-grown oesophagus, providing a transformative solution for children born with Oesophageal Atresia. This tissue-engineered breakthrough uses a patient's own cells to create a functional organ, potentially eliminating the need for high-risk invasive surgeries.